Crohn's Disease Clinical Trial
Official title:
NIH SUBSTUDY:Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single Infusions of AIN457 in Patients With Moderate to Severe Active Crohn's Disease
The objective of this NIH-specific substudy is immunologic monitoring of cytokine and immune cell responses in subjects undergoing treatment with AIN457 (human monoclonal anti-human interleukin-17A) for moderate to severe Crohn's disease. Recent data suggests that interleukin-17 (IL-17) is an important mediator of inflammation in certain animal models of Crohn's disease, and treatment aimed at blocking the IL-23-IL-17 axis can ameliorate the inflammatory changes. In addition, elevated expression of IL-l7 has been found in the gut tissue of patients with active Crohn's disease. This substudy will measure changes in cytokine production, relevant RNA expression, and immune cell populations (in the periphery and lamina propria) for correlation with clinical outcomes in order to explore the mechanisms of therapeutic response.
Purpose:
- Crohn's disease is an inflammatory bowel disease with major symptoms such as diarrhea
and abdominal pain when the disease is in an active stage.
- AIN457 is a protein developed by NOVARTIS that is used to stop the action of
Interleukin-17 (IL-17), a protein made by the body that contributes to many different
kinds of inflammatory diseases, including Crohn's disease. AIN457 is being developed
for the potential treatment of various inflammatory diseases like rheumatoid arthritis
and psoriasis, but has not been tested for suitability in people with Crohn's disease.
Objectives:
- The main objective of the NIH substudy is to obtain additional blood and gut biopsy
tissue for monitoring biochemical changes in immune variables in response to study drug
or placebo.
- The main objective of the main multicenter study (sponsored by NOVARTIS) is to
determine whether AIN457 is safe and effective in the treatment of Crohn's disease, and
if effective, how long the effect will remain.
Eligibility:
- Important eligibility criteria to consider for patients to be enrolled in the AIN457 trial
include:
Inclusion criteria:
- Male or female; 18-75 years old
- Diagnosis of Crohn's disease for at least 3 months prior to screening
- Moderate to severe active Crohn's disease at baseline, defined as: CDAI greater than or
equal to 220 and less than or equal to 450
- Active disease despite prior treatment with stable dose of corticosteroids for 2 weeks,
or immunosuppressant for at least 3 months (e.g. methotrexate, azathioprine).
Exclusion criteria:
- Subjects with symptoms associated with active bowel stricturing disease and
pre-stenotic dilation on radiography.
- Fistulizing disease if complicated by sepsis and/or untreated abscess.
- Subjects with multiple bowel surgeries and clinically important short bowel syndrome
defined as an inability to maintain caloric intake.
- Prior therapy with rituximab.
- Receiving corticosteroids dose equivalent to a > 40mg dose of prednisone per day.
- Subjects demonstrating clinical improvement due to other Crohn's therapy.
- Subjects with active or history of clinically significant cardiac abnormalities.
Design:
- For the NIH substudy, additional blood will be drawn and a colonoscopy will be
performed before the first infusion and after the second infusion.
- The multicenter study plans to enroll seventy-two (72) subjects with moderate to severe
active Crohn's disease that is not controlled by corticosteroids, immunosuppressant
(e.g. methotrexate or purine metabolites) or anti-inflammatory treatment (e.g. 5-ASA).
At baseline visit, if the eligibility of the subject is confirmed, the subject will be
randomized (2:1 ratio) to receive either AIN457 or placebo administered as a 2 hours
intravenous infusion. A total of two infusions will be given on day 1 and day 22
respectively.
- After infusions there will be a follow-up period of up to 18 weeks.
- Once this study is completed, an extension study will be conducted that will offer
access to AIN457. Patients who complete the current study may be eligible to enter the
extension study and receive therapy with AIN457.
;
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03815851 -
Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery
|
N/A | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Completed |
NCT02883452 -
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis
|
Phase 1 | |
Recruiting |
NCT04777656 -
Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients.
|
Phase 3 | |
Terminated |
NCT03017014 -
A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
|
||
Recruiting |
NCT06053424 -
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease
|
Phase 1 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Not yet recruiting |
NCT02858557 -
The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases
|
N/A | |
Terminated |
NCT02882841 -
MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients
|
N/A | |
Terminated |
NCT02417974 -
Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)
|
Phase 2 | |
Completed |
NCT02542917 -
Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
|
||
Completed |
NCT03010787 -
A First Time in Human Study in Healthy Volunteers and Patients
|
Phase 1 | |
Active, not recruiting |
NCT02316678 -
Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics
|
N/A | |
Completed |
NCT02154425 -
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
|
Phase 1 | |
Completed |
NCT02193048 -
Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
|
||
Completed |
NCT02197780 -
Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD
|
N/A | |
Completed |
NCT02265588 -
Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).
|
N/A | |
Recruiting |
NCT02395354 -
Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease
|
N/A | |
Completed |
NCT01958827 -
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
|
Phase 3 |